Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 4/20 | 0.55 |
| ▸ | MAOB | P27338 | 4/20 | 0.55 |
| ▸ | BCHE | P06276 | 1/20 | 0.55 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.55 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.55 |
| ▸ | ACHE | P22303 | 1/20 | 0.55 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.55 |
| ▸ | HTR6 | P50406 | 1/20 | 0.55 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.51 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.49 |
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.48 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.48 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.48 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | FADS1 | O60427 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3895376 | 1.00 | MAOA (0.55) | MAOAMAOBBCHEADRA2BADRA2C | |
| SCHEMBL13618840 | 1.00 | MAOA (0.55) | MAOAMAOBBCHEADRA2BADRA2C | |
| SCHEMBL13618839 | 1.00 | MAOA (0.55) | MAOAMAOBBCHEADRA2BADRA2C | |
| SCHEMBL13618837 | 1.00 | MAOA (0.55) | MAOAMAOBBCHEADRA2BADRA2C | |
| SCHEMBL3415622 | 1.00 | MAOA (0.55) | MAOAMAOBBCHEADRA2BADRA2C | |
| Oxalic Acid SCHEMBL3421257 | 0.93 | MAOA (0.49) | MAOAMAOBBCHEADRA2BADRA2C | |
| SCHEMBL3421683 | 0.84 | MAOA (0.55) | MAOAMAOBBCHEADRA2BADRA2C | |
| SCHEMBL13651749 | 0.84 | MAOA (0.55) | MAOAMAOBBCHEADRA2BADRA2C | |
| SCHEMBL3421666 | 0.84 | MAOA (0.55) | MAOAMAOBBCHEADRA2BADRA2C | |
| SCHEMBL9499569 | 0.82 | MAOA (0.63) | MAOAMAOBBCHEADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2381767-B1 | DELAYED RELEASE RASAGILINE FORMULATION | TEVA PHARMA (IL) | 2016-01-20 | — | — | EP | claimed |
| EP-2308477-B1 | Delayed release rasagiline formulation | TEVA PHARMA (IL) | 2012-05-09 | — | — | EP | claimed |
| US-8080584-B2 | Delayed release rasagiline citrate formulation | TEVA PHARMACEUTICALS INDUSTRIES, LTD. (IL) | 2011-12-20 | — | — | US | claimed |
| EP-2308477-A1 | Delayed release rasagiline formulation | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2011-04-13 | — | — | EP | claimed |
| EP-2218444-A2 | Delayed release rasagiline formulation | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2010-08-18 | — | — | EP | claimed |
| US-20100189787-A1 | Delayed release rasagiline citrate formulation | TEVA PHARMACEUTICAL INDUSTRIES, LTD. | 2010-07-29 | — | — | US | claimed |
| US-20100189788-A1 | Delayed release rasagiline base formulation | TEVA PHARMACEUTICAL INDUSTRIES, LTD. | 2010-07-29 | — | — | US | claimed |
| US-20100189791-A1 | Delayed release rasagiline malate formulation | TEVA PHARMACEUTICAL INDUSTRIES, LTD. | 2010-07-29 | — | — | US | claimed |
| EP-2381767-B1 | DELAYED RELEASE RASAGILINE FORMULATION | TEVA PHARMA (IL) | 2016-01-20 | — | — | EP | disclosed |
| US-20140186514-A1 | DELAYED RELEASE RASAGILINE FORMULATION | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2014-07-03 | — | — | US | disclosed |
| US-20120263789-A1 | DELAYED RELEASE RASAGILINE FORMULATION | TEVA PHARMACEUTICAL INDUSTRIES LTD. | 2012-10-18 | — | — | US | disclosed |
| WO-2012066366-A1 | NEW SALTS SUITABLE FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS | EGIS GYŐGYSZERGYÁR NYILVÁNOSAN MŰKÖDÖ RÉSZVÉNYTÁR-SASÁG (HU) | 2012-05-24 | — | — | WO | disclosed |
| EP-2308477-B1 | Delayed release rasagiline formulation | TEVA PHARMA (IL) | 2012-05-09 | — | — | EP | disclosed |
| US-20120100189-A1 | DELAYED RELEASE RASAGILINE MALATE FORMULATION | TEVA PHARMACEUTICAL INDUSTRIES LTD. | 2012-04-26 | — | — | US | disclosed |
| US-7598420-B1 | Rasagiline formulations and processes for their preparation | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2009-10-06 | — | — | US | disclosed |
| US-7598420-B1 | Rasagiline formulations and processes for their preparation | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2009-10-06 | — | — | US | disclosed |
| US-7598420-B1 | Rasagiline formulations and processes for their preparation | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2009-10-06 | — | — | US | disclosed |
| US-7572834-B1 | Rasagiline formulations and processes for their preparation | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2009-08-11 | — | — | US | disclosed |
| US-7572834-B1 | Rasagiline formulations and processes for their preparation | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2009-08-11 | — | — | US | disclosed |
| US-7572834-B1 | Rasagiline formulations and processes for their preparation | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2009-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120100189-A1 | DELAYED RELEASE RASAGILINE MALATE FORMULATION | MDH1, MDH2, SLC25A11 | MAOA 2404/4885MAOB 1645/4885BCHE 1564/4885 |
| US-20140186514-A1 | DELAYED RELEASE RASAGILINE FORMULATION | RAB7A, RAB27A, RAB35 | MAOA 384/4885MAOB 294/4885BCHE 679/4885 |
| US-20100189787-A1 | Delayed release rasagiline citrate formulation | CS, SDHA, SUCNR1 | MAOA 1447/4885MAOB 1046/4885BCHE 644/4885 |
| US-20100189788-A1 | Delayed release rasagiline base formulation | RAB7A, RAB27A, RAB5B | MAOA 643/4885MAOB 237/4885BCHE 844/4885 |
| US-20100189791-A1 | Delayed release rasagiline malate formulation | MDH1, MDH2, SLC25A11 | MAOA 2404/4885MAOB 1645/4885BCHE 1564/4885 |
| US-20120263789-A1 | DELAYED RELEASE RASAGILINE FORMULATION | RAB7A, RAB27A, RAB35 | MAOA 384/4885MAOB 294/4885BCHE 679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.